Ramipril ist der meistverordnete Blutdrucksenker in Deutschland – mit über 4,7 Milliarden definierten Tagesdosen pro Jahr. Als ACE-Hemmer senkt er nicht nur den Blutdruck, sondern schützt auch Herz und Nieren. Doch eine Nebenwirkung kennt fast jeder Betroffene: den typischen trockenen Reizhusten.
.gif)
Ramipril is a prescription medication. Never stop on your own initiative. For sudden swelling of the lips, face, or tongue: call 999 or go to A&E immediately.
Ramipril is one of the most widely prescribed ACE inhibitors in the UK. ACE inhibitors not only lower blood pressure — they simultaneously protect the heart, kidneys, and blood vessels. Ramipril has one of the strongest cardiovascular evidence bases of any antihypertensive, established by the HOPE trial (2000), making it the preferred agent in high-risk prevention.
| Property | Details |
|---|---|
| Active substance | Ramipril (prodrug → active metabolite: ramiprilat) |
| ATC code | C09AA05 (ACE inhibitors, plain) |
| Drug class | ACE inhibitor (angiotensin-converting enzyme inhibitor) |
| Available forms | Tablets / capsules (1.25 mg, 2.5 mg, 5 mg, 10 mg) |
| Half-life | Ramipril: approx. 3 h; ramiprilat (active): 13–17 h |
| Max. daily dose | 10 mg |
| Onset of action | 1–2 hours; full blood pressure reduction after 3–4 weeks |
| Prescription only | Yes |
| Special feature | Extensive cardiovascular evidence (HOPE trial 2000) |
Ramipril — like all ACE inhibitors — is a prodrug: after absorption it is converted in the liver into its active metabolite ramiprilat. Ramiprilat blocks the angiotensin-converting enzyme (ACE), which plays a central role in the renin-angiotensin-aldosterone system (RAAS). In brief: the RAAS is the hormonal system that regulates blood pressure and kidney function. When overactive, blood pressure rises. Ramipril puts the brakes on it.
Specifically, ramiprilat inhibits the conversion of angiotensin I to angiotensin II — one of the most potent vasoconstrictors in the body. Less angiotensin II means: wider blood vessels, lower blood pressure, less aldosterone (the kidneys excrete more water and sodium), and reduced cardiac workload.
The HOPE trial (2000, Yusuf et al.) is one of the most important milestones in cardiology: in high-risk patients (heart disease, diabetes + additional risk factor), ramipril reduced myocardial infarction, stroke, and cardiovascular death by 22% — beyond the pure blood pressure effect alone. Ramipril also prevents harmful remodelling of the heart muscle after infarction and in heart failure. Record all cardiac medications in your digital medication plan.
For the kidneys: ramipril reduces the pressure in the kidney filters (glomeruli) and reduces urinary protein excretion (proteinuria). It is therefore the agent of choice in diabetic nephropathy — it demonstrably slows the progression of kidney disease.
ACE not only converts angiotensin I — it also inactivates bradykinin. Under ramipril, bradykinin levels rise. This has two sides: more bradykinin dilates blood vessels (positive, amplifies the blood pressure effect) and has anti-inflammatory effects (positive). But: bradykinin also irritates the bronchial mucosa — this explains the typical ACE inhibitor dry cough, affecting up to 20% of patients.
The most important rule with ramipril: never start at the target dose. ACE inhibitors can cause a pronounced blood pressure drop at the start of therapy — particularly in patients also taking diuretics, in heart failure, or with dehydration. The dose is therefore always titrated: a low starting dose, increased every 2–4 weeks.
| Indication | Starting dose | Target dose | Titration |
|---|---|---|---|
| Hypertension | 1.25–2.5 mg/day | 2.5–10 mg/day | Double every 2–4 weeks |
| Heart failure | 1.25 mg/day | 10 mg/day (2 × 5 mg) | Double every 1–2 weeks |
| After myocardial infarction | 2.5 mg twice daily | 5 mg twice daily | Increase after 2 days |
| Renal protection (nephropathy) | 1.25 mg/day | 5 mg/day | Titrate slowly |
| Cardiovascular prevention | 2.5 mg/day | 10 mg/day | Increase every 1–3 weeks |
| eGFR (ml/min) | Max. daily dose | Note |
|---|---|---|
| ≥ 60 | 10 mg | No restriction |
| 30–59 | 5 mg | Monitor kidney values + potassium regularly |
| <30 | 2.5 mg | Close monitoring; starting dose 1.25 mg |
Ramipril can be taken independently of meals — food does not affect absorption. Timing is flexible: morning is standard, but for elevated nocturnal blood pressure the doctor may recommend evening intake. The TIME trial (2022) showed that timing matters less than daily regularity.
The ACE inhibitor dry cough affects up to 20% of patients — and is the most common reason for stopping therapy. It is dry, persistent, non-productive, and can appear shortly after starting or even months later. The cause: bradykinin levels rise under ramipril and chemically irritate the bronchial mucosa — which is why cough suppressants or cold remedies do not help.
The only effective solution: switch to a sartan (candesartan, valsartan, etc.). Sartans block the angiotensin II receptor directly, do not interfere with bradykinin metabolism, and therefore do not cause a cough. Blood pressure reduction and organ protection are comparable. Anyone suffering from a dry cough: speak to the doctor — don't put up with it for months.
| Side effect | Frequency | What to do |
|---|---|---|
| Dry irritant cough | Common (up to 20%) | Inform doctor; switch to sartan if needed |
| Dizziness / blood pressure drop | Common | Especially at start of therapy; rise slowly |
| Headaches, fatigue | Common | Often improves after 1–2 weeks |
| Hyperkalaemia (raised potassium) | Common | Monitor potassium levels regularly |
| Skin rash, itching | Occasional | Inform doctor |
| Taste disturbance (metallic) | Occasional | Usually transient |
| Renal impairment | Occasional | Monitor kidney values + potassium |
| Angioedema (swelling of face/throat) | Rare (0.1–0.2%) | EMERGENCY — call 999, stop ramipril immediately! |
Ramipril has some clinically significant interactions. By far the most common in everyday practice: the combination with NSAIDs — often unintentional, because patients reach for over-the-counter ibuprofen without consulting. Check all combinations with the interaction check.
Known in nephrology as the "Triple Whammy": concurrent use of an ACE inhibitor (ramipril) + NSAID (ibuprofen) + diuretic (e.g. HCTZ or furosemide). Each of these three medications moderately impairs kidney function on its own. All three together can trigger acute kidney failure — even with previously normal kidney values. This combination occurs frequently because patients buy ibuprofen OTC without knowing they are already on an ACE inhibitor and a diuretic.
| Substance / medication | Interaction | Recommendation |
|---|---|---|
| Ibuprofen / diclofenac (NSAIDs) | Reduces blood pressure-lowering effect + increases kidney injury risk | Prefer paracetamol (acetaminophen)! With short-term NSAIDs: monitor kidney values |
| Potassium supplements / high-potassium diet | Ramipril raises potassium — extra potassium can cause hyperkalaemia | No extra potassium without medical monitoring |
| Potassium-sparing diuretics (spironolactone) | Substantially elevated hyperkalaemia risk | Only with close potassium monitoring |
| Lithium | Ramipril reduces lithium excretion → levels rise | Monitor lithium levels more frequently |
| Sacubitril/valsartan (Entresto) | Elevated angioedema risk | At least 36 hours gap! |
| Aliskiren | Dual RAAS blockade — hyperkalaemia, kidney injury | Contraindicated with diabetes or eGFR <60 |
| Metformin | Ramipril may mildly lower blood glucose | Monitor blood glucose more frequently at start of therapy |
| Alcohol | Enhances blood pressure-lowering effect | Limit intake, especially at start of therapy |
